Despite growing evidence highlighting the relevance of increasing IL-10-producing B cells (B10 + cells) in autoimmune diseases, their functions in patients are still unknown. The aim of this study was to evaluate the functions of CpG-induced B10
+ cells isolated from healthy controls (HC) and rheumatoid arthritis (RA) patients, on naïve T cell differentiation. We demonstrated that CpG-induced B10
+ cells from HC drove naïve T cell differentiation toward regulatory T cells (Treg cells) and IL-10-producing T cells (Tr1) through IL-10 secretion and cellular contacts. B10
+ cells from HC did not decrease T helper 1 (Th1) nor and tumor necrosis factor α producing T cell (TNFα + T cell) differentiation. We showed that in RA, B10
+ cells could also induce Treg cells and Tr1 from naïve T cells. Contrary to HC, B10
+ cells from RA patients increased naïve T cell conversion into Th1. Interestingly, PD-L2, a programmed death-1 (PD-1) ligand that inhibits PD-L1 and promotes Th1 differentiation, was overexpressed on RA B10
+ cells compared to HC B10 + cells. Together, our findings showed that CpG-induced B10 + cells may be used to increase Treg cells in patients with RA. However, CpG may not be the most adequate stimuli as CpG-induced B10
+ cells also increased inflammatory T cells in those patients.
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inTrODUcTiOn Breakdown of immune tolerance can lead to the development of autoimmune diseases such as rheumatoid arthritis (RA). While the causes of such breakdown are not fully known, a key feature is the expansion of pro-inflammatory T cell subsets T helper 1 (Th1), Th17, and tumor necrosis factor α producing T cells (TNFα + T cells) and, by contrast, the decrease of regulatory T (Treg) cell subsets. Both Tregs subsets, characterized either by the markers FoxP3 and CD4
+

CD25
hi CD127
low/neg (Treg cells) or by IL-10 secretion (Tr1), are able to limit the expansion of pro-inflammatory T cells. Similarly, auto-reactive B cells, which promote inflammation through the secretion of auto-antibodies, pro-inflammatory cytokines, or via antigen-presentation are increased, whereas regulatory B cells (Breg cells) are decreased. The role of Breg cells in tolerance has been established in both preclinical and clinical studies (1, 2) . Indeed, the absence of Breg cells in mice has been shown to exacerbate the development of arthritis (3) while their adoptive transfer significantly decreases autoimmune disease severity in mouse models, such as experimental autoimmune encephalitis (4), colitis (5) , and arthritis (6) . Human studies have also showed impaired number and function of Breg cells in patients with auto immune and chronic inflammatory diseases (7) (8) (9) (10) . Thus, increasing the number of functional Breg cells in those patients could restore a balanced regulatory vs inflammatory response. + B cells is comparable to those in healthy patients, they have lost the ability to induce Treg cells or to decrease Th1 and TNFα + T cells (7, 8, 12) . Thus, a marker for Breg cells which closely correlates with their functions is needed, both in healthy individuals and in patients. As both CD24 hi CD38
hi and CD24 hi CD27
+ B cells are able to produce IL-10 after a stimulation with CpG, IL-10 production has been extensively used to define Breg cells, also known as B10
+ cells (12, 15, 16) . However, it is unknown whether any type of B cell secreting IL-10 has regulatory functions, in healthy subjects and in patients. Indeed, while the functions of CD24 hi CD38
hi and CD24 hi CD27 + B cells have been extensively described, CpG-induced B10
+ cell regulatory functions remain fully elusive.
The objective of this study was to determine whether CpG-induced IL-10-producing B cells is a relevant functional definition for Breg cells in healthy subjects and in patients with RA.
MaTerials anD MeThODs subjects
Healthy subjects were either blood donors or patients seen in the department of Rheumatology (Teaching hospital, Montpellier) for mild osteoarthritis or mechanical pain with no general pathology or infection and receiving no immunomodulatory drugs. To be included, patients with RA had to fulfill ACR/EULAR 2010 criteria, be free of biological disease-modifying anti-rheumatic drugs and have no glucocorticoid or less than 10 mg/day. All subjects signed a written informed consent for the study in accordance with the 2013 Declaration of Helsinki and as approved by the Medical Ethics Committee of Nimes hospital, France (CPP_2012-A00592-41). Characteristics of the controls and patients are detailed in Table 1 .
T cell isolation
Blood was collected in EDTA K2 tubes. PBMCs were isolated from 10 mL of whole blood using Ficoll-Paque Plus (GE Healthcare, Aulnay-sous-bois, France), cultivated on 96-well plate at 1.5 × 10 6 cells/mL for 24 h in filtered complete media (RPMI 1640 with 10% fetal calf serum, penicillin and streptomycin). The day after, PBMCs were stained and sorted using FACS ARIA III (BD biosciences). To isolate CD4
+
CD25
− cells, we used FITC-conjugated anti-CD4 (clone RPA-T4, BD Pharmingen) and PE-conjugated anti-CD25 (clone BC96, ebioscience, Thermofisher, USA) antibodies. To sort naïve CD4 + CD45RA + CD62L + cells, we used APC eFluor 780-conjugated anti-CD4 (RPA-T4, ebioscience), FITCconjugated anti-CD62L (clone DREG-56, BD Pharmingen), and PerCP Cy5.5-conjugated anti-CD45RA (clone HI100 BD Pharmingen) antibodies. Dead cells were excluded using DAPI staining. Gating strategies are shown Figure S1 in Supplementary Material.
B10
+ cell isolation B cells were isolated from 50 mL of whole blood using RosetteSep human B enrichment (StemCell, Grenoble France), followed by a Ficoll separation. As tested previously (12) , B cells were cultivated in complete media at 3 × 10 6 cells/mL and stimulated with plate bound CD40L (1 µg/mL, Peprotech, Neuilly sur Seine, France), and CpG (10 µg/mL, ODN 2006, InvivoGen, Toulouse, France) for 24 h to generate B10 + cells. IL-10 secretion was activated by adding Phorbol 12-myristate 13-acetate (PMA) (0.1 µg/mL, BioVision, Nanterre, France) and ionomycin (0.5 µg/mL, BioVision) for the last 4 h of culture. After stimulation, B10
+ cells were stained using IL-10 secretion assay from Miltenyi biotec (Paris, France) according to the manufacturer's instructions. Briefly, B cells were first incubated for 5 min on ice with IL-10-specific catch reagent that can attach both leukocyte surface and IL-10. Then B cells were incubated during 45 min at 37°C, to allow IL-10 secretion. The secreted IL-10 bound to the IL-10 Catch Reagent attached on secreting cells. IL-10 secreting cells were then detected using a second IL-10-specific antibody, the IL-10 Detection Antibody conjugated to R-phycoerythrin (PE). At this last step, an APCconjugated anti-CD19 antibody (clone HIB19, BD Pharmingen) was also added. After staining, B cells were sorted using FACS ARIA III (BD bioscience), into two populations: B cells with positive IL-10 staining (referred to as B10 + cells) and cells with negative IL-10 staining (referred to as B10 neg cells). Dead cells were excluded using DAPI staining. Gating strategies are shown in Figure S1 in Supplementary Material.
cytokines assessment
PBMCs from healthy individuals were stimulated by CpG (10 µg/mL) for 24 h. PMA and ionomycin were then added for the last 4 h of culture and BFA (10 µg/mL, Sigma Aldrich) was added for the last 2 h. PBMCs were then stained using FITC or V450-conjugated anti CD19 (clone HIB19, BD Pharmingen) and Fixable Viability Dye eFluor 506 (Thermofisher) before fixation (cytofix/cytoperm buffer BD biosciences) and permeabilization (Perm wash buffer, BD Pharmingen). Intracellular staining for IL-10, IFNγ, and TNFα was then performed using APCconjugated anti IL-10 (clone JES3-19F1, BD Pharmingen) and PeCy7-conjugated anti-IFNγ PeCy7 (4SB3, BD Pharmingen) or anti-TNFα (clone MAb11, BD Pharmingen). Percentages of IFNγ and TNFα positive cells among B10
+ and B10 neg cells were measured by flow cytometry, using FACS CANTO II (BD biosciences). Gating strategy and representative flow cytometry dot plot are shown in Figure S2 in Supplementary Material. We also measured cytokines concentrations in supernatants from isolated B10
+ and B10 neg cells. To do this, B10 + and B10 neg cells were sorted as described above, and kept in culture for 24 h. Then, cytokine dosages in supernatants were performed using Human IFN-γ ELISA MAX Deluxe and Human TNF-α ELISA MAX Deluxe (BioLegend, San Diego, CA, USA) according to the manufacturer's instructions.
cell co-culture and conversion assay From naïve T cells to Treg, Tr1, Th1, and TnFα + T cells
Isolated T cells were cultured either alone or in a ratio 1:1 with autologous sorted B cell subsets (B10 + or with B10 neg cells) in complete media, stimulated with plate bound anti-CD3 (dose 1 µg/mL) during 72 h. For Treg cell staining, FITC or APCefluor780-conjugated anti-CD4, PE-conjugated anti-CD25 and PeCy5-conjugated anti-CD127 (clone eBioRDR5, eBioscience) antibodies were used. Dead cells were excluded using DAPI staining. Treg cells were defined as CD4
+ CD127 low/neg . Tr1, Th1, and TNFα + T cell intracellular staining was performed after activation with PMA and ionomycin the last 4 h of culture and then BFA was added for the last 2 h of culture. Cells were stained with FITC conjugated anti-CD4 (clone RPA-T4, BD Pharmingen) or APC-efluor780 conjugated anti-CD4 (clone RPA-T4 ebioscience) antibodies before fixation and permeabilization. T cells cytokine secretion was then assessed using APC-conjugated anti-IFNγ (clone B27, BD Pharmingen), PeCy7-conjugated anti-TNFα (clone MAb11, BD Pharmingen), and PE-conjugated anti-IL-10 (clone JES3-9D7, eBioscience) antibodies. A fixable viability dye efluor506 discriminant was used according to the manufacturer's instructions. Data were acquired by a FACS CANTO II. Th1 were defined as CD4 Anti-IL-10 (clone JES3-9D7, BD Pharmingen), anti CD80 (B7.1, clone 2D10.4, ebioscience), and anti CD86 (clone IT2.2, BD Pharmingen) were added directly into the media. All the inhibitors were used at 10 µg/mL during 72 h. Percentages of Treg cells were assessed by flow cytometry after 72 h.
statistical analysis
Comparison between paired data were performed using Wilcoxon matched pairs test. Significance was ascribed to p values <0.05. To compare variations between healthy controls (HC) and patients, we expressed data as median ± interquartile range (IQR) 25-75 and significance was assessed using Mann-Whitney test. All analyses were performed in Graph Pad Prism 5 (San Diego, CA, USA (Figures 2A,B) + and B10 neg cells, respectively; p = 0.02; n = 7) (Figures 2C,D) .
These results were confirmed in a co-culture using CD4 + and B10 neg , respectively; p = 0.02; n = 7) (Figures 2E,F) . (Figure 3A) . However, Treg cell conversion was not solely attributable to IL-10 since addition of recombinant IL-10 (10 and 100 ng/mL) to B10 neg cells could not lead to the same increase in Treg cells ( Figure 3A) . To test whether cellular contacts were needed to generate Treg cells, we separated B10 + and T cells with a membrane insert, so that cytokine transfers were still effective but direct contacts were prevented. We found that cellular contacts were essential since adding insert to the co-cultures lead to a drastic decrease in Treg cells (Treg decrease of 90% [80.56; 93.33]; p = 0.02; n = 7) (Figures 3B,C) .
To further characterize the cellular interactions between B10 + cells and T cells, we assessed the surface expression on B10 + cells and on B10 neg cells of the co-stimulatory molecules CD80, CD86, and the program death molecule ligands 1 and 2 (PD-L1 and PD-L2), known to trigger Treg cell functions. We found that all of them, with the exception of CD86, were more often expressed and with a higher level of expression on B10
+ cells compared to B10 neg cells ( Figure 3D ; Figure S3 in Supplementary Material). We then assessed the effect of blocking these costimulatory molecules on Treg cell differentiation. (Figures 4C,D) . 
B10
+ cells From ra Patients effectively convert naïve T cells into Treg cells and Tr1 but also increased the Proportion of Th1
B10
+ cell deficiency seems to play an important role in autoimmune diseases, however, B10
+ functions in patients have poorly been studied. As observed in HC, we found that B10 
+ cells From ra Patients expressed a higher ratio of PD-l2 to PD-l1 Than in hc PD-L1 was shown to inhibit Th1 differentiation whereas PD-L2 could promote it (18, 19 (Figures 6A,B) leading to a higher ratio of PD-L2
+ to PD-L1 + on RA B10 + cells ( Figure 6C ). This variation in PD-L1 and PD-L2 expression was also true when analyzing their expression levels by median of fluorescence intensity ( Figure 6D ). This might explain why RA B10 + cells induced Th1 differentiation but not HC B10 + cells.
DiscUssiOn
The aim of the present study was to determine whether CpGinduced IL-10-producing B cells were a relevant functional definition for regulatory B cells in healthy subjects and in patients with RA. (19) showed that in co-culture of unexperienced B cells and CD4 + T cells, blocking PD-L2 inhibited IFNγ production whereas neutralizing PD-L1 enhanced proliferation and IFNγ production. In the same way, Karunarathne et al. (18) found that PD-L2 expressed on dendritic cells, by inhibiting PD-1 binding to PD-L1, increased T cell activation and improved Th1 response. In our study, because of the low number of B10 + cells in RA patients, we could not perform functional experiment to confirm PDLs involvement in Th1 differentiation.
Notably, PD-L1 and PD-1 blocking antibody have been used in cancer therapies (21) . As PDLs seem to be implicated in Breg cell functions, further studies could be useful to support the choice between PD-L1 or PD-1 blocking antibodies in treating cancer.
Together, our findings show that CpG-induced B10 + cells may be used to increase Tregs in patients with RA but not to decrease pro-inflammatory T cells.
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